{
    "organizations": [],
    "uuid": "ccaead25f420e0964ce891e56ebb9bc6f6ffd715",
    "author": "",
    "url": "https://www.reuters.com/article/brief-syndax-announces-immuno-oncology-c/brief-syndax-announces-immuno-oncology-clinical-trial-collaboration-with-astrazeneca-idUSASB0C3GT",
    "ord_in_thread": 0,
    "title": "BRIEF-Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 15 PM / in 15 minutes BRIEF-Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca Reuters Staff \nFeb 1 (Reuters) - Syndax Pharmaceuticals Inc: \n* SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA \n* SYNDAX PHARMACEUTICALS INC - CO & ASTRAZENECA TO COLLABORATE ON NON-EXCLUSIVE BASIS TO EVALUATE COMBINATION OF TWO DRUGS IN MULTIPLE SOLID TUMOR TYPES \n* SYNDAX PHARMACEUTICALS INC - SYNDAX EXPECTS TO INITIATE A PHASE IB STUDY IN FIRST HALF OF 2018 \n* SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED Source text for Eikon: Further company coverage:",
    "published": "2018-02-01T14:14:00.000+02:00",
    "crawled": "2018-02-01T14:39:21.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "announces",
        "clinical",
        "trial",
        "collaboration",
        "astrazeneca",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "syndax",
        "pharmaceutical",
        "inc",
        "syndax",
        "announces",
        "clinical",
        "trial",
        "collaboration",
        "astrazeneca",
        "syndax",
        "pharmaceutical",
        "inc",
        "co",
        "astrazeneca",
        "collaborate",
        "basis",
        "evaluate",
        "combination",
        "two",
        "drug",
        "multiple",
        "solid",
        "tumor",
        "type",
        "syndax",
        "pharmaceutical",
        "inc",
        "syndax",
        "expects",
        "initiate",
        "phase",
        "ib",
        "study",
        "first",
        "half",
        "syndax",
        "pharmaceutical",
        "inc",
        "financial",
        "term",
        "agreement",
        "disclosed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}